Neurodegenerative Disorders: Integrated Biomarkers and Imaging for AD, PD, and MS

Juan Moises de la Serna compiled this integrated database in 2026, synthesizing molecular biomarkers, neuroimaging metrics, and clinical progression scales for Alzheimer's, Parkinson's, and Multiple Sclerosis. The data covers research and clinical reports published between 2013 and 2026, focusing specifically on neuroinflammatory mechanisms across these three conditions.

Use Cases

• Comparing neurofilament light chain (NfL) levels across MS, AD, and PD to identify disease-specific inflammatory signatures
• Evaluating the correlation between T2-FLAIR lesion counts and EDSS progression rates in Multiple Sclerosis
• Statistical analysis of odds ratios for genetic risk factors like HLA-DRB1 in relation to global prevalence data

Strengths

• Integration of three distinct data modalities: molecular, imaging, and clinical progression
• Includes longitudinal metrics such as annual brain atrophy rates and clinical progression scales
• Synthesizes data from high-authority sources including WHO, Mayo Clinic, and MSBase

Limitations

• Secondary data source containing synthesized values from literature rather than raw, individual patient-level observations
• Methodological dependency on AI-assisted systematic search which may introduce search-term bias
• Lack of explicit record counts for the underlying meta-analyses

Provenance

Source

Peer-reviewed literature, meta-analyses, and global health reports (WHO, PMC/NCBI, Mayo Clinic, MSBase)

Collection Method

Perplexity AI systematic search and meta-synthesis

Time Range

2013-2026

Freshness

Updated through February 2026, including clinical trial data from 2020-2024.

Geography

Global